Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapyJames R. Berenson, Robert Vescio, James Hilger et al.|Leukemia|2014Cited by 76
Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myelomaJames R. Berenson, Robert Vescio, Gary K. Schwartz et al.|British Journal of Haematology|2022Cited by 12
Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).James R. Berenson, Robert Vescio, James Hilger et al.|Journal of Clinical Oncology|2013Cited by 3
Ruxolitinib and Methylprednisolone for Treatment of Patients with Relapsed/Refractory Multiple MyelomaJames R. Berenson, Robert Vescio, Daisy Martinez et al.|Blood|2022Cited by 2
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and MethylprednisoloneJames R. Berenson, Robert Vescio, Andrea Limon et al.|Targeted Oncology|2024Cited by 2